PTGER3
Reaktivität: Human
WB, ELISA, IHC, IF
Wirt: Kaninchen
Polyclonal
unconjugated
Applikationshinweise
Optimal working dilution should be determined by the investigator.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
0.5-0.6 μg/μL
Yokoyama, Xin, Shigeto, Mizunuma: "Combination of ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, and cisplatin enhances the inhibition of growth of human ovarian cancers." in: Journal of cancer research and clinical oncology, Vol. 137, Issue 8, pp. 1219-28, (2011) (PubMed).
Target
PTGER3
(Prostaglandin E Receptor 3 (Subtype EP3) (PTGER3))